CliffBio
small molecule

SAVELLA

MILNACIPRAN HYDROCHLORIDE

Loss of exclusivitySeptember 2029latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSAVELLA
Active ingredientMILNACIPRAN HYDROCHLORIDE
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2009
Marketing statusRX

Listed patents

PatentExpiresType
7994220September 2029use U-819

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SAVELLA patent cliff — loss of exclusivity September 2029 | CliffBio